Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (494)	2/20/1999 1:52:00 PM
From: muddphudd	Read Replies (1) \| Respond to of 586

MORE COMPETITION: MALVERN, Pa. (CBS.MW) -- Biotechnology company Centocor said Tuesday it is seeking approval to sell its Remicade drug in a much larger market -- the treatment of arthritis. Centocor (CNTO) filed a Food and Drug Administration application for the drug, currently approved only to treat Crohn's disease. The company has been testing the drug as a treatment for rheumatoid arthritis, a form of arthritis that afflicts 2.5 million people in the United States. Centocor reported its FDA application was partially based on Phase III Remicade data on the drug's impact on people with rheumatoid arthritis. The testing will continue for up to two years to determine the long-term effectiveness of the drug. The company is studying 428 patients in 34 testing areas throughout the United States and Europe, Centocor said. "In this trial, we are also interested in learning if Remicade will ultimately lead to prevention of structural damage and improvement in functional ability," Richard McCloskey, chief medical officer, said in a statement. THEY ARE USING A VERY SIMILAR APPROACH AS IMMUNEX: TARGETING TUMOR NECROSIS FACTOR (TNF). I JUST GAVE A PRESENTATION ON THERAPEUTICS FOR RHEUMATOID ARTHRITIS AND ANTI-TNF THERAPIES WERE ALL THE BUZZ. THERE WERE SOME QUESTIONS ABOUT THE PROSORBA COLUMN AS WELL.